Wei Li, Lin Zexiao, Xie Sidong, Ruan Danyun, Jiang Wen, Cui Yueli, Liu Sisi, Wang Tiantian, Chen Zhanhong, Lin Qu
Department of Oncology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Department of Radiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Front Oncol. 2022 Feb 16;12:798515. doi: 10.3389/fonc.2022.798515. eCollection 2022.
Metastases typically develop before diagnosis and during the treatment of colorectal cancers, while patients with metastatic colorectal cancers (mCRCs) currently have a poor prognosis. In terms of surgical approaches, adjuvant therapies, and targeted therapies, the treatment of mCRCs has had numerous recent advances. As a targeted agent widely used in mCRCs, cetuximab-based treatment is still under dispute due to its side effects and unstable effect. We present two mCRC cases treated with cetuximab-based therapy, of which two patients achieved complete response and without recurrence for over 22 and 84 months, respectively. To better understand the drug usage, we also reviewed the recent achievements and usage precautions of cetuximab in mCRCs. Present and many previous observations support that cetuximab might be a referred drug in the first-line chemotherapy of mCRCs with wild-type and and proficient mismatch repair.
转移通常在结直肠癌诊断前和治疗期间发生，而转移性结直肠癌（mCRC）患者目前预后较差。在手术方法、辅助治疗和靶向治疗方面，mCRC的治疗最近有了许多进展。作为一种广泛用于mCRC的靶向药物，基于西妥昔单抗的治疗因其副作用和疗效不稳定仍存在争议。我们报告了两例接受基于西妥昔单抗治疗的mCRC病例，其中两名患者分别获得完全缓解且在超过22个月和84个月内无复发。为了更好地了解药物使用情况，我们还回顾了西妥昔单抗在mCRC中的最新成果和使用注意事项。目前以及许多先前的观察结果支持，西妥昔单抗可能是错配修复野生型和 proficient型mCRC一线化疗中的推荐药物。
